CER Daily Newsfeed

The Comparative Effectiveness Research Daily Newsfeed®, known for short as the CER Daily Newsfeed®, offers the latest news, research and related information on comparative effectiveness research, real-world data and evidence, value assessment and other important health care topics. 

News from Tuesday, January 25, 2022

Articles

Semaglutide Linked With Better Outcomes vs Dulaglutide in Type 2 Diabetes

(1/24, Colby Stong, Medical Bag) reports “Patients with type 2 diabetes (T2D) had significantly greater reductions in glycated hemoglobin (HbA1c) and body weight with semaglutide vs dulaglutide, according to results published in the Journal of Clinical Endocrinology & Metabolism. Both are glucagon-like peptide-1 receptor agonists (GLP-1 RAs), drugs which are often used as a treatment option in people with T2D.” Full

 

Less Selling, More Science Can Best Help Doctors Navigate Complex New Cancer Treatments, Report Suggests

(1/23, Natalie Missakian, Fierce Pharma) reports “...The [Accenture] report found 65% of oncologists want pharma reps to be able to discuss real-world data with them; more than half (51%) said they ‘will need more discussion’ on real-world data from reps in the future. The report also suggests machine-assisted decision-making, where technology is employed to match patients with suitable treatments, will increasingly trump sales reps when it comes to doctors' cancer drug decisions.” Full

 

RWE Alliance Commends FDA Draft Guidance for EHR Data Use

(1/25, Hannah Nelson, EHR Intelligence) reports “...‘FDA’s draft guidance for using EHRs and medical claims data in regulatory decision making represents a key step on our journey toward standardized methods for evaluating and analyzing RWD,’ Jeremy Rassen, co-founder and president at Aetion, noted in a press release. ‘These methods are a necessary component of high-quality and credible RWE, and the level of detail in the guidance signals FDA’s commitment to advancing the use of EHR and claims data in product submissions,’ he added. ‘We are pleased to share our experience and insights with the Agency as it works to finalize the guidance.’” Full

 

Califf on Path to Win FDA Chief Role Despite Expected 'No' Votes

(1/24, Celine Castronuovo and Alex Ruoff, Bloomberg Law) reports “...Califf would return to the agency as it grapples with concerns over its independence and credibility, which lawmakers have called into question amid the Covid-19 pandemic. Analysts say he's poised to bring steady leadership and clear direction. Several Democrats, however, have said they aren't convinced Califf would take steps to strengthen opioid safety regulations amid an addiction crisis that's gotten worse over the pandemic.” Paid Subscription Required

Press Releases

Prospection and Novotech Partner To Accelerate Clinical Trials With Real World Evidence

(1/24, Prospection Press Release) “...Under the partnership, Prospection will become a technology partner of Novotech, providing its proprietary real world data analytics to support clinical trial feasibility assessment, execution and recruitment in the Asia-Pacific region. ‘Real world evidence has reached a value inflection point becoming broadly accepted and increasingly utilised by regulatory authorities, as we’ve seen with its application to help manage COVID-19. The combination of our real world data analytics with Novotech’s clinical development expertise and footprint across the Asia-Pacific region brings together two nimble companies focused on generating evidence to support healthcare innovation and ultimately improve health outcomes for patients,’ said CEO Eric Chung.” Full

Journals

B.1.617.2 SARS-CoV-2 (Delta) Variant Is Associated with Increased Risk of Hospitalization and Death Compared with B.1.1.7 SARS-CoV-2 (Alpha) Variant

Eduardo Freire Rodrigues, et al.

January 23, 2022, medRxiv

medRxiv